Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report
Caihong Fu, Lei Yang, Hui Qiao, Xiting Liu, Jiexin Wang · 2025
Read Long-term survival after ALK-TKI resistance through immunotherapy combined with chemotherapy in ALK-positive non-small cell lung cancer: a case report by Caihong Fu, Lei Yang, Hui Qiao, Xiting Liu, Jiexin Wang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12740855.txt.
Description
Caihong Fu and co-authors report a case from 2025 of long survival in lung cancer after targeted drugs stopped working. The patient's cancer carried a gene fusion for which targeted pills work well at first. Most patients gain years before the cancer adapts and grows again. What to do next has no agreed standard, and immune drugs are disputed in this cancer type, since they often fail there.
This patient worsened fast through two rounds of targeted pills, plus radiation to the main tumor and spread sites. Care then switched to standard chemotherapy joined with an immune drug. The cancer shrank and stayed controlled for more than forty-five months, far beyond the usual span. The authors present the case as a sign that the immune-plus-chemo route deserves study after resistance. They also call for rules on when to try it.
Catalog record
| CREATOR | Caihong Fu, Lei Yang, Hui Qiao, Xiting Liu, Jiexin Wang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |